ArticleTherapeutic advances in medical oncology2021

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer.

Teng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.